Frequentist and Bayesian meta-regression of health state utilities for multiple myeloma incorporating systematic review and analysis of individual patient data

被引:19
作者
Hatswell, Anthony J. [1 ,2 ]
Burns, Darren [3 ]
Baio, Gianluca [1 ]
Wadelin, Frances [4 ]
机构
[1] UCL, Dept Stat Sci, London, England
[2] Univ Nottingham, Univ Hosp, Delta Hat Ltd, Nottingham, England
[3] Univ Nottingham, BresMed, Univ Hosp, Sheffield, S Yorkshire, England
[4] Nottingham Univ Hosp, Nottingham, England
关键词
EQ-5D; cost-effectiveness; multiple myeloma; utility synthesis; QUALITY-OF-LIFE; COST-EFFECTIVENESS; EORTC QLQ-C30; METAANALYSIS; THERAPY; SCORES; VALUES; POPULATION; NUMBER; IMPACT;
D O I
10.1002/hec.3871
中图分类号
F [经济];
学科分类号
02 ;
摘要
This analysis presents the results of a systematic review for health state utilities in multiple myeloma, as well as analysis of over 9,000 observations taken from registry and trial data. The 27 values identified from 13 papers are then synthesised in a frequentist nonparametric bootstrap model and a Bayesian meta-regression. Results were similar between the frequentist and Bayesian models with low utility on disease diagnosis (approximately 0.55), raising to approximately 0.65 on first line treatment and declining slightly with each subsequent line. Stem cell transplant was also found to be a significant predictor of health-related quality of life in both individual patient data and meta-regression, with an increased utility of approximately 0.06 across different models. The work presented demonstrates the feasibility of Bayesian methods for utility meta-regression, whilst also presenting an internally consistent set of data from the analysis of registry data. To facilitate easy updating of the data and model, data extraction tables and model code are provided as Data S1. The main limitations of the model relate to the low number of studies available, particularly in highly pretreated patients.
引用
收藏
页码:653 / 665
页数:13
相关论文
共 35 条
[1]   Impact of the treatment-free interval on health-related quality of life in patients with multiple myeloma: a UK cross-sectional survey [J].
Acaster, S. ;
Gaugris, S. ;
Velikova, G. ;
Yong, K. ;
Lloyd, A. J. .
SUPPORTIVE CARE IN CANCER, 2013, 21 (02) :599-607
[2]  
[Anonymous], NICE GUID METH TECHN
[3]  
[Anonymous], 2017, RSTAN R INTERFACE ST
[4]   ESTIMATING EORTC-8D HEALTH STATE UTILITY VALUES FROM EORTC QLQ-C30 SCORES IN RELAPSED MULTIPLE MYELOMA [J].
Ashaye, A. O. ;
Altincatal, A. ;
Bender, R. H. ;
Zhang, J. ;
Panjabi, S. .
VALUE IN HEALTH, 2015, 18 (07) :A468-A468
[5]   MAPPING UTILITY SCORES FROM EUROPEAN ORGANIZATION FOR TREATMENT OF CANCER CORE-30 QUESTIONNAIRE SCORES (EORTC QLQ-C30) IN RELAPSED MULTIPLE MYELOMA [J].
Ashaye, A. O. ;
Zhang, J. ;
Bender, R. H. ;
Altincatal, A. ;
Panjabi, S. .
VALUE IN HEALTH, 2015, 18 (03) :A208-A208
[6]   The number of subjects per variable required in linear regression analyses [J].
Austin, Peter C. ;
Steyerberg, Ewout W. .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 2015, 68 (06) :627-636
[7]  
Canty A., 2016, BOOT BOOTSTRAP R SPL
[8]   An assessment of the external validity of mapping QLQ-C30 to EQ-5D preferences [J].
Crott, Ralph ;
Versteegh, Matthijs ;
Uyl-de-Groot, Carin .
QUALITY OF LIFE RESEARCH, 2013, 22 (05) :1045-1054
[9]  
Davison A, 1997, BOOTSTRAP METHODS TH, V1
[10]   Cost-effectiveness of zoledronic acid compared with clodronate in multiple myeloma [J].
Delea, T. E. ;
El Ouagari, K. ;
Rotter, J. ;
Wang, A. ;
Kaura, S. ;
Morgan, G. J. .
CURRENT ONCOLOGY, 2012, 19 (06) :E392-E403